Publications by authors named "A E CHIRON"
LiCoPO and LiNiPO phosphate pigments have colorations very close to the primary colors of the subtractive system: magenta and yellow, respectively. These two pigments are therefore of great interest in a variety of applications, including e-reader devices. However, the need to reduce their crystallite size in order to formulate stable electrophoretic inks has revealed that aggressive milling results in significant color changes, particularly for cobalt-based pigments.
View Article and Find Full Text PDFIn recent years, following the groundbreaking achievements of chimeric antigen receptor (CAR) T cell therapy in hematological cancers, and advancements in cell engineering technologies, the exploration of other immune cells has garnered significant attention. CAR-Therapy extended beyond T cells to include CAR natural killer (NK) cells and CAR-macrophages, which are firmly established in the clinical trial landscape. Less conventional immune cells are also making their way into the scene, such as CAR mucosal-associated invariant T (MAIT) cells.
View Article and Find Full Text PDFBackground: Multiple sclerosis (MS) may occur before the age of 18. Differentiation between paediatric MS (PedMS) and other demyelinating syndromes (ODSs) is challenging. In adult with MS, the kappa free light chain (KFLC) index has proven to be a reliable marker of intrathecal Ig synthesis.
View Article and Find Full Text PDFArticle Synopsis
- Erythropoiesis-stimulating agents like erythropoietin (EPO) may negatively affect cancer patients due to their immunosuppressive properties.
- * In a mouse model of triple-negative breast cancer, EPO was found to promote tumor growth, create an 'immune desert,' and contribute to a 'cold tumor,' altering the immune cell distribution in various body areas.
- * EPO treatment specifically accelerates the activation and exhaustion of CD4 T cells, leading to an immunosuppressive tumor microenvironment, with a notable CD39 regulatory T cell population identified as a potential biomarker for increased tumor progression risk.
Despite chronic primary pain being recognized as a disease in the 11th revision of the International Classification of Diseases (ICD-11), individuals suffering from it are still too frequently met with a certain skepticism. This skepticism can detrimentally affect their healthcare journey, social life, and economic stability. This article outlines part of the legal evolution regarding the recognition of chronic pain as well as the current insurance-related provisions in Switzerland.
View Article and Find Full Text PDF